Henry Schein's Quiet Handoff After Four Decades of One CEO

Part of Distributor Playbooks — strategy teardowns of every company on the 2025 MDM Top Distributors lists.

Henry Schein sits at No. 6 on the Pharma & Healthcare list in Modern Distribution Management's 2025 Top Distributors report, the trade publication's annual ranking of North America's largest wholesalers, on $12.3 billion in 2024 revenue. That scale did not come from a founding family holding tight to the wheel for a century. It came from the opposite: a company that gave up family control decades ago and then, strangely, ran with more continuity than most family businesses ever manage.

A Pharmacy, a Pivot, and a Non-Family Handoff

The company started in 1932 when Henry Schein borrowed $500 and opened a pharmacy in Queens. His sons Marvin and then Jay Schein took over daily operations and later the CEO seat, and the business grew modestly until it pivoted into dental supplies in the 1960s. That is the recognizable founder-story beat. What happened next is the unusual part: when Jay Schein died of cancer in 1989, the company did not pass to a third-generation Schein. It went to Stanley Bergman, a South African-born accountant who had joined nine years earlier as CFO. Bergman then ran the company as CEO for the next 35 years, per Wikipedia's account of the company's history, taking it public in 1995 and, by his own later account, growing revenue from $225 million in 1989 to nearly $13 billion in 2024.

The Insight: Two CEOs, Ninety Years, One Roll-Up Machine

Here is the thing a competitor's strategy team should actually sit with. Henry Schein has not been family-owned in any operating sense since Bergman took the chair, yet it has been run with the kind of multi-decade continuity that family ownership is supposed to provide and that PE-rolled-up distributors almost never have. Two chief executives across roughly ninety years, each promoted from inside after a long apprenticeship, is close to unheard of in a sector where private equity now flips distributors every five to seven years. That continuity is what let Henry Schein compound an acquisition strategy patiently instead of opportunistically: the 1997 purchase of Sullivan Dental for roughly $318 million, which made Henry Schein the world's largest dental equipment and supply distributor, was one deal among something like 200 acquisitions the company completed between 1989 and 2016, steadily layering in medical products and veterinary supplies on top of the dental base. A roll-up strategy usually needs either a founding family's patience or a sponsor's discipline to hold together. Henry Schein got the patience part from a non-family CEO who simply stayed for 35 years.

Knowing What to Cut

The same discipline showed up in reverse in 2019, when Henry Schein spun off its animal health distribution arm and merged it with Vets First Choice to form the standalone company Covetrus. Having spent two decades building veterinary distribution into a real category leg, the company concluded that leg no longer belonged under the same roof as the dental and medical business. Distributors love to talk about category expansion. Fewer are willing to talk about category subtraction, and Henry Schein's willingness to unwind a business it had spent twenty years assembling is a better signal of institutional discipline than any acquisition count.

The Model Underneath: Wallet Share, Not Just Boxes

The physical network is comparatively lean for the revenue it moves: roughly five U.S. distribution centers spanning about two million square feet, according to public descriptions of the company's supply chain, supporting dental and medical practices nationwide. The bigger lever is software stickiness. Henry Schein One, the practice-management joint venture anchored by the Dentrix platform, ties scheduling, imaging, and billing to the same account that buys consumables and equipment, converting distribution scale into recurring, harder-to-switch revenue per practice rather than one-off box sales. That is the logic behind the company's 2025-2027 "BOLD+1" plan, which SEC filings describe as resting on three pillars: core distribution and value-added services, owned-brand self-manufacturing, and technology integration.

The Handoff Nobody in Distribution Saw Coming

Two things happened almost simultaneously heading into 2026, and either one alone would be a big story for a company this size. In January 2025, KKR built a stake in Henry Schein and struck a deal for board representation, according to Reuters — a private equity firm buying into a public distributor's boardroom rather than buying the whole company outright, which is the reverse of the usual take-private playbook this sector has run for a decade. Then in July 2025 Bergman announced he would retire as CEO at the end of the year after 45 years with the company, staying on as chairman, with Modern Distribution Management reporting the succession. His replacement, effective in early 2026, is Frederick Lowery, a former Thermo Fisher Scientific executive — the first Henry Schein CEO in nearly a century who was not promoted up through the company itself, per MDM's report on the appointment.

That is a real strategic bet, and it cuts both ways. An outside operator from a scientific-instruments giant brings fresh eyes to executing BOLD+1's manufacturing and technology pillars, plus a PE partner's balance-sheet discipline. It also means the company is retiring the exact leadership continuity that let it integrate 200 acquisitions without the churn that plagues PE-owned rivals, at the precise moment it needs to prove that discipline still holds without the person who built it.

Every distributor on this list wins or loses on the same unglamorous inputs: what is in the catalog, how fast a branch can fill an order, and whether the data behind both is trustworthy enough to bet a business on.